Careers  |  Sign In  |  Register  |   Twitter

Study Finds Diabetes Drug Does Not Reduce CV Events

Reuters reports that the type 2 diabetes medication Onglyza “failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.” AstraZeneca and Bristol-Myers Squibb jointly announced that a recent “trial showed that patients on Onglyza had no fewer adverse cardiovascular events, such as heart attacks and strokes, than those on placebo.” Patients with diabetes “are at increased risk of suffering a heart attack or stroke,” so the test was of particular interest for the drug which already sold $709 million in 2012.

Read the article published by Reuters.